Evidence map›Paper›PMID 38971895›Full record

Trial reportMolecular psychiatry2025

Thalamocortical functional connectivity and rapid antidepressant and antisuicidal effects of low-dose ketamine infusion among patients with treatment-resistant depression.

Pei-Chi Tu, Wan-Chen Chang, Tung-Ping Su, Wei-Chen Lin, Cheng-Ta Li, Ya-Mei Bai, Shih-Jen Tsai, Mu-Hong Chen

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Molecular psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. MedComm · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Pei-Chi TuDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0002-9403-4660
Wan-Chen ChangDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Tung-Ping SuDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Wei-Chen LinDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Cheng-Ta LiDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0002-0670-1153
Ya-Mei BaiDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.
Shih-Jen TsaiDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan.ORCID 0000-0002-9987-022X
Mu-Hong ChenDepartment of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan. kremer7119@gmail.com.ORCID 0000-0001-6516-1073

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have shown an association between the thalamocortical dysconnectivity and treatment-resistant depression (TRD). Whether a single subanesthetic dose of ketamine may change thalamocortical connectivity among patients with TRD is unclear. Whether these changes in thalamocortical connectivity is associated with the antidepressant and antisuicidal effects of ketamine treatment is also unclear. Two resting-state functional MRIs were collected in two clinical trials of 48 patients with TRD (clinical trial 1; 32 receiving ketamine, 16 receiving a normal saline placebo) and 48 patients with TRD and strong suicidal ideation (clinical trial 2; 24 receiving ketamine, 24 receiving midazolam), respectively. All participants underwent rs-fMRI before and 3 days after infusion. Seed-based functional connectivity (FC) was analyzed in the left/right thalamus. FCs between the bilateral thalamus and right middle frontal cortex (BA46) and between the left thalamus and left anterior paracingulate gyrus (BA8) increased among patients in the ketamine group in clinical trials 1 and 2, respectively. FCs between the right thalamus and bilateral frontal pole (BA9) and between the right thalamus and left rostral paracingulate gyrus (BA10) decreased among patients in the ketamine group in clinical trials 1 and 2, respectively. However, the associations between those FC changes and clinical symptom changes did not survive statistical significance after multiple comparison corrections. Whether ketamine-related changes in thalamocortical connectivity may be associated with ketamine's antidepressant and antisuicidal effects would need further investigation. Clinical trials registration: UMIN Clinical Trials Registry (UMIN-CTR): Registration number: UMIN000016985 and UMIN000033916.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantKetamineMagnetic Resonance ImagingThalamusAdultCerebral CortexDouble-Blind MethodFemaleHumansMaleMiddle AgedNeural PathwaysSuicidal IdeationAntidepressive AgentsKetamine

Identifiers

PMID38971895
PMCPMC11649554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.